Tumor targeting via EPR: Strategies to enhance patient responses
The tumor accumulation of nanomedicines relies on the enhanced permeability and
retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there …
retention (EPR) effect. In the last 5–10 years, it has been increasingly recognized that there …
[HTML][HTML] Targeted therapy for breast cancer: An overview of drug classes and outcomes
AT Jacobs, DM Castaneda-Cruz, MM Rose… - Biochemical …, 2022 - Elsevier
The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …
termed targeted therapies based on their ability to block specific pathways known to drive …
Trastuzumab emtansine: mechanisms of action and drug resistance
M Barok, H Joensuu, J Isola - Breast cancer research, 2014 - Springer
Abstract Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and
generally well tolerated when administered as a single agent to treat advanced breast …
generally well tolerated when administered as a single agent to treat advanced breast …
Tumor necrosis factor α blockade: an opportunity to tackle breast cancer
MF Mercogliano, S Bruni, PV Elizalde… - Frontiers in …, 2020 - frontiersin.org
Breast cancer is the most frequently diagnosed cancer and the principal cause of mortality
by malignancy in women and represents a main problem for public health worldwide. Tumor …
by malignancy in women and represents a main problem for public health worldwide. Tumor …
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
C Vernieri, M Milano, M Brambilla, A Mennitto… - Critical reviews in …, 2019 - Elsevier
HER2-positive breast cancer (HER2+ BC) represents 15–20% of all BCs. In the last two
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
J Baselga, SM Swain - Nature Reviews Cancer, 2009 - nature.com
Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb)
family plays a crucial part in the development and evolution of cancer. Inhibiting the …
family plays a crucial part in the development and evolution of cancer. Inhibiting the …
Resistance to trastuzumab
S Vivekanandhan, KL Knutson - Cancers, 2022 - mdpi.com
Simple Summary Trastuzumab is a humanized antibody that has significantly improved the
management and treatment outcomes of patients with cancers that overexpress HER2 …
management and treatment outcomes of patients with cancers that overexpress HER2 …
[HTML][HTML] HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
C Grávalos, A Jimeno - Annals of oncology, 2008 - Elsevier
Gastric cancer is the second leading cause of cancer mortality in the world and its
management, especially in advanced stages, has evolved relatively little. In particular, no …
management, especially in advanced stages, has evolved relatively little. In particular, no …
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
D Gajria, S Chandarlapaty - Expert review of anticancer therapy, 2011 - Taylor & Francis
HER2 amplification is seen in up to 20% of breast cancers and is associated with an
aggressive phenotype. Trastuzumab, a monoclonal antibody to HER2, accrues significant …
aggressive phenotype. Trastuzumab, a monoclonal antibody to HER2, accrues significant …
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
Trastuzumab is a monoclonal antibody targeted against the human epidermal growth factor
receptor (HER) 2 tyrosine kinase receptor, which is overexpressed in approximately 25% of …
receptor (HER) 2 tyrosine kinase receptor, which is overexpressed in approximately 25% of …